FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1432-1444 October 5, 2006 Number 14 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Perspective by Steinbrook, R. Editorial by Stone, E. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background We compared ranibizumab — a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A — with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration.

Methods During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months.

Results Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P<0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%).

Conclusions Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov] .)

Source Information

From Vitreoretinal Consultants, Methodist Hospital, Houston (D.M.B.); the Cole Eye Institute, Cleveland Clinic Foundation, Cleveland (P.K.K.); Retina Care Specialists, Palm Beach Gardens, FL (M.M.); the Clinique d'Ophtalmologie, University of Paris XII, Créteil, France (G.S.); Ophthalmic Consultants of Boston, Boston (J.S.H.); and Genentech, South San Francisco, CA (R.Y.K., J.P.S., S.S.).

Address reprint requests to Dr. Brown at Vitreoretinal Consultants, 6560 Fannin St., Suite 750, Houston, TX 77030, or at dmbmd{at}houstonretina.com.

Full Text of this Article

Related Letters:

Ranibizumab for Neovascular Age-Related Macular Degeneration
Liew G., Mitchell P., Gillies M. C., Wong T. Y., Rosenfeld P. J., Brown D. M., Schneider S., the MARINA and ANCHOR Study Groups
Extract | Full Text | PDF  
N Engl J Med 2007; 356:747-750, Feb 15, 2007. Correspondence

This article has been cited by other articles:

• Patel, P. J., Browning, A. C., Chen, F. K., Cruz, L. D., Tufail, A. (2009). Interobserver Agreement for the Detection of Optical Coherence Tomography Features of Neovascular Age-Related Macular Degeneration. IOVS 50: 5405-5410 [Abstract] [Full Text]  
• Galbinur, T, Averbukh, E, Banin, E, Hemo, I, Chowers, I (2009). Intravitreal bevacizumab therapy for neovascular age-related macular degeneration associated with poor initial visual acuity. Br J Ophthalmol 93: 1351-1352 [Abstract] [Full Text]  
• Luke, M, Januschowski, K, Luke, J, Peters, S, Wirtz, N, Yoruk, E, Luke, C, Bartz-Schmidt, K U, Grisanti, S, Szurman, P (2009). The effects of ranibizumab (Lucentis) on retinal function in isolated perfused vertebrate retina. Br J Ophthalmol 93: 1396-1400 [Abstract] [Full Text]  
• Suner, I. J., Kokame, G. T., Yu, E., Ward, J., Dolan, C., Bressler, N. M. (2009). Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical Trials. IOVS 50: 3629-3635 [Abstract] [Full Text]  
• Shah, A R, Priore, L V D. (2009). Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br J Ophthalmol 93: 1027-1032 [Abstract] [Full Text]  
• Ahlers, C., Golbaz, I., Einwallner, E., Dunavolgyi, R., Malamos, P., Stock, G., Pruente, C., Schmidt-Erfurth, U. (2009). Identification of Optical Density Ratios in Subretinal Fluid as a Clinically Relevant Biomarker in Exudative Macular Disease. IOVS 50: 3417-3424 [Abstract] [Full Text]  
• Kashani, A. H., Keane, P. A., Dustin, L., Walsh, A. C., Sadda, S. R. (2009). Quantitative Subanalysis of Cystoid Spaces and Outer Nuclear Layer Using Optical Coherence Tomography in Age-Related Macular Degeneration. IOVS 50: 3366-3373 [Abstract] [Full Text]  
• Avci, B., Avci, R., Inan, U. U., Kaderli, B. (2009). Comparative Evaluation of Apoptotic Activity in Photoreceptor Cells after Intravitreal Injection of Bevacizumab and Pegaptanib Sodium in Rabbits. IOVS 50: 3438-3446 [Abstract] [Full Text]  
• Chua, P. Y. S., Mitrut, I., Armbrecht, A.-M., Vani, A., Aslam, T., Dhillon, B. (2009). Evaluating Patient Discomfort, Anxiety, and Fear Before and After Ranibizumab Intravitreous Injection for Wet Age-Related Macular Degeneration. Arch Ophthalmol 127: 939-940 [Full Text]  
• Hawkins, B. S., Bressler, N. M., Reynolds, S. M. (2009). Visual Acuity Outcomes Among Sham vs No-Treatment Controls From Randomized Trials. Arch Ophthalmol 127: 725-731 [Abstract] [Full Text]  
• Karnon, J., Czoski-Murray, C., Smith, K. J., Brand, C. (2009). A Hybrid Cohort Individual Sampling Natural History Model of Age-Related Macular Degeneration: Assessing the Cost-Effectiveness of Screening Using Probabilistic Calibration. Med Decis Making 29: 304-316 [Abstract]  
• Chong, E. W.-T., Robman, L. D., Simpson, J. A., Hodge, A. M., Aung, K. Z., Dolphin, T. K., English, D. R., Giles, G. G., Guymer, R. H. (2009). Fat Consumption and Its Association With Age-Related Macular Degeneration. Arch Ophthalmol 127: 674-680 [Abstract] [Full Text]  
• Acharya, N, Lois, N, Townend, J, Zaher, S, Gallagher, M, Gavin, M (2009). Socio-economic deprivation and visual acuity at presentation in exudative age-related macular degeneration. Br J Ophthalmol 93: 627-629 [Abstract] [Full Text]  
• Sayanagi, K, Sharma, S, Kaiser, P K (2009). Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration. Br J Ophthalmol 93: 622-626 [Abstract] [Full Text]  
• Chen, F. K., Patel, P. J., Uppal, G. S., Rubin, G. S., Coffey, P. J., Aylward, G. W., Da Cruz, L. (2009). A Comparison of Macular Translocation with Patch Graft in Neovascular Age-Related Macular Degeneration. IOVS 50: 1848-1855 [Abstract] [Full Text]  
• Takahashi, K., Saishin, Y., Saishin, Y., King, A. G., Levin, R., Campochiaro, P. A. (2009). Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib. Arch Ophthalmol 127: 494-499 [Abstract] [Full Text]  
• Rein, D. B., Wittenborn, J. S., Zhang, X., Honeycutt, A. A., Lesesne, S. B., Saaddine, J., for the Vision Health Cost-Effectiveness Study Gro, (2009). Forecasting Age-Related Macular Degeneration Through the Year 2050: The Potential Impact of New Treatments. Arch Ophthalmol 127: 533-540 [Abstract] [Full Text]  
• Enzmann, V., Yolcu, E., Kaplan, H. J., Ildstad, S. T. (2009). Stem Cells as Tools in Regenerative Therapy for Retinal Degeneration. Arch Ophthalmol 127: 563-571 [Abstract] [Full Text]  
• Chong, E. W.-T., Simpson, J. A., Robman, L. D., Hodge, A. M., Aung, K. Z., English, D. R., Giles, G. G., Guymer, R. H. (2009). Red Meat and Chicken Consumption and Its Association With Age-related Macular Degeneration. Am J Epidemiol 169: 867-876 [Abstract] [Full Text]  
• Murjaneh, S, Garcia-Finana, M, Mahmood, S, Lenfestey, P M, Taylor, S A, Pearce, I A, Briggs, M C, Heimann, H, Harding, S P (2009). Observational prospective study of the effectiveness in routine clinical practice of verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration. Br J Ophthalmol 93: 468-473 [Abstract] [Full Text]  
• Kim, I. K, Gragoudas, E. S (2009). Radiation therapy for neovascular age-related macular degeneration revisited. Br J Ophthalmol 93: 279-280 [Full Text]  
• Avila, M P, Farah, M E, Santos, A, Duprat, J P, Woodward, B W, Nau, J (2009). Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 93: 305-309 [Abstract] [Full Text]  
• Ayoub, T., Patel, N. (2009). Age-related macular degeneration. JRSM 102: 56-61 [Full Text]  
• Bressler, N. M., Chang, T. S., Fine, J. T., Dolan, C. M., Ward, J., for the Anti-VEGF Antibody for the Treatment of Pr, (2009). Improved Vision-Related Function After Ranibizumab vs Photodynamic Therapy: A Randomized Clinical Trial. Arch Ophthalmol 127: 13-21 [Abstract] [Full Text]  
• Zhang, J., Cao, R., Zhang, Y., Jia, T., Cao, Y., Wahlberg, E. (2009). Differential roles of PDGFR-{alpha} and PDGFR-{beta} in angiogenesis and vessel stability. FASEB J. 23: 153-163 [Abstract] [Full Text]  
• Krohne, T U, Hunt, S, Holz, F G (2009). Effect of 308 nm excimer laser irradiation on retinal pigment epithelium cell viability in vitro. Br J Ophthalmol 93: 91-95 [Abstract] [Full Text]  
• Fung, A. E, Bhisitkul, R. B (2008). Safety monitoring with ocular anti-vascular endothelial growth factor therapies. Br J Ophthalmol 92: 1573-1574 [Full Text]  
• Schmidt-Erfurth, U, Wolf, S, for the PROTECT Study Group, (2008). Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 92: 1628-1635 [Abstract] [Full Text]  
• Arias, L, Caminal, J M, Casas, L, Masuet, C, Badia, M B, Rubio, M, Pujol, O, Arruga, J (2008). A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 92: 1636-1641 [Abstract] [Full Text]  
• O'Doherty, M, Dooley, I, Hickey-Dwyer, M (2008). Interventions for diabetic macular oedema: a systematic review of the literature. Br J Ophthalmol 92: 1581-1590 [Abstract] [Full Text]  
• Liakopoulos, S., Ongchin, S., Bansal, A., Msutta, S., Walsh, A. C., Updike, P. G., Sadda, S. R. (2008). Quantitative Optical Coherence Tomography Findings in Various Subtypes of Neovascular Age-Related Macular Degeneration. IOVS 49: 5048-5054 [Abstract] [Full Text]  
• Podbielski, D. W., Noble, J. (2008). Answer: Answer to Ophthaproblem. cfp 54: 1396-1398 [Full Text]  
• Hernandez-Pastor, L. J., Ortega, A., Garcia-Layana, A., Giraldez, J. (2008). Ranibizumab for neovascular age-related macular degeneration. Am J Health Syst Pharm 65: 1805-1814 [Abstract] [Full Text]  
• Patel, P. J., Chen, F. K., Rubin, G. S., Tufail, A. (2008). Intersession Repeatability of Visual Acuity Scores in Age-Related Macular Degeneration. IOVS 49: 4347-4352 [Abstract] [Full Text]  
• Bhisitkul, R. B., Winn, B. J., Lee, O.-T., Wong, J., Pereira, D. d. S., Porco, T. C., He, X., Hahn, P., Dunaief, J. L. (2008). Neuroprotective Effect of Intravitreal Triamcinolone Acetonide against Photoreceptor Apoptosis in a Rabbit Model of Subretinal Hemorrhage. IOVS 49: 4071-4077 [Abstract] [Full Text]  
• Anderson, O. A., Jackson, T. L., Singh, J. K., Hussain, A. A., Marshall, J. (2008). Human Transscleral Albumin Permeability and the Effect of Topographical Location and Donor Age. IOVS 49: 4041-4045 [Abstract] [Full Text]  
• Karanjia, R, Eng, K T, Gale, J, Sharma, S, Hove, M W t. (2008). Electrophysiological effects of intravitreal Avastin (bevacizumab) in the treatment of exudative age-related macular degeneration. Br J Ophthalmol 92: 1248-1252 [Abstract] [Full Text]  
• Augood, C., Chakravarthy, U., Young, I., Vioque, J., de Jong, P. T., Bentham, G., Rahu, M., Seland, J., Soubrane, G., Tomazzoli, L., Topouzis, F., Vingerling, J. R, Fletcher, A. E (2008). Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Am. J. Clin. Nutr. 88: 398-406 [Abstract] [Full Text]  
• Mendis, R, Leslie, T, McBain, V, Lois, N (2008). Combined therapy for retinal angiomatous proliferation with intravitreal triamcinolone and argon laser photocoagulation. Br J Ophthalmol 92: 1154-1156 [Full Text]  
• Kaempf, S., Johnen, S., Salz, A. K., Weinberger, A., Walter, P., Thumann, G. (2008). Effects of Bevacizumab (Avastin) on Retinal Cells in Organotypic Culture. IOVS 49: 3164-3171 [Abstract] [Full Text]  
• Keane, P. A., Liakopoulos, S., Ongchin, S. C., Heussen, F. M., Msutta, S., Chang, K. T., Walsh, A. C., Sadda, S. R. (2008). Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular Degeneration. IOVS 49: 3115-3120 [Abstract] [Full Text]  
• Chang, L. K., Spaide, R. F., Brue, C., Freund, K. B., Klancnik, J. M. Jr, Slakter, J. S. (2008). Bevacizumab Treatment for Subfoveal Choroidal Neovascularization From Causes Other Than Age-Related Macular Degeneration. Arch Ophthalmol 126: 941-945 [Abstract] [Full Text]  
• Tatar, O., Yoeruek, E., Szurman, P., Bartz-Schmidt, K. U., Adam, A., Shinoda, K., Eckardt, C., Boeyden, V., Claes, C., Pertile, G., Scharioth, G. B., Grisanti, S. (2008). Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization. Arch Ophthalmol 126: 782-790 [Abstract] [Full Text]  
• Chong, E. W-T., Kreis, A. J., Wong, T. Y., Simpson, J. A., Guymer, R. H. (2008). Dietary {omega}-3 Fatty Acid and Fish Intake in the Primary Prevention of Age-Related Macular Degeneration: A Systematic Review and Meta-analysis. Arch Ophthalmol 126: 826-833 [Abstract] [Full Text]  
• Lux, A, Llacer, H, Heussen, F M A, Joussen, A M (2008). Authors' reply. Br J Ophthalmol 92: 865-866 [Full Text]  
• Odergren, A, Algvere, P V, Seregard, S, Kvanta, A (2008). A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. Br J Ophthalmol 92: 757-761 [Abstract] [Full Text]  
• Mochimaru, H., Usui, T., Yaguchi, T., Nagahama, Y., Hasegawa, G., Usui, Y., Shimmura, S., Tsubota, K., Amano, S., Kawakami, Y., Ishida, S. (2008). Suppression of Alkali Burn-Induced Corneal Neovascularization by Dendritic Cell Vaccination Targeting VEGF Receptor 2. IOVS 49: 2172-2177 [Abstract] [Full Text]  
• Stewart, M W, Rosenfeld, P J (2008). Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 92: 667-668 [Abstract] [Full Text]  
• Berdugo, M., Bejjani, R. A., Valamanesh, F., Savoldelli, M., Jeanny, J.-C., Blanc, D., Ficheux, H., Scherz, A., Salomon, Y., BenEzra, D., Behar-Cohen, F. (2008). Evaluation of the New Photosensitizer Stakel (WST-11) for Photodynamic Choroidal Vessel Occlusion in Rabbit and Rat Eyes. IOVS 49: 1633-1644 [Abstract] [Full Text]  
• Kiuchi, K., Matsuoka, M., Wu, J. C., Lima e Silva, R., Kengatharan, M., Verghese, M., Ueno, S., Yokoi, K., Khu, N. H., Cooke, J. P., Campochiaro, P. A. (2008). Mecamylamine Suppresses Basal and Nicotine-Stimulated Choroidal Neovascularization. IOVS 49: 1705-1711 [Abstract] [Full Text]  
• Cook, H. L., Patel, P. J., Tufail, A. (2008). Age-related macular degeneration: diagnosis and management. Br Med Bull 85: 127-149 [Abstract] [Full Text]  
• Weigert, G, Michels, S, Sacu, S, Varga, A, Prager, F, Geitzenauer, W, Schmidt-Erfurth, U (2008). Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 92: 356-360 [Abstract] [Full Text]  
• Csaky, K. G., Richman, E. A., Ferris, F. L. III (2008). Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. IOVS 49: 479-489 [Full Text]  
• Goverdhan, S V, Lochhead, J (2008). Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol 92: 210-212 [Abstract] [Full Text]  
• Marneros, A. G., She, H., Zambarakji, H., Hashizume, H., Connolly, E. J., Kim, I., Gragoudas, E. S., Miller, J. W., Olsen, B. R. (2007). Endogenous endostatin inhibits choroidal neovascularization. FASEB J. 21: 3809-3818 [Abstract] [Full Text]  
• Chong, E. W-T, Wong, T. Y, Kreis, A. J, Simpson, J. A, Guymer, R. H (2007). Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 335: 755-755 [Abstract] [Full Text]  
• Mochimaru, H., Nagai, N., Hasegawa, G., Kudo-Saito, C., Yaguchi, T., Usui, Y., Kurihara, T., Koto, T., Satofuka, S., Shinoda, H., Ozawa, Y., Tsubota, K., Kawakami, Y., Ishida, S. (2007). Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2. IOVS 48: 4795-4801 [Abstract] [Full Text]  
• Submacular Surgery Trials Research Group, (2007). Incident Choroidal Neovascularization in Fellow Eyes of Patients With Unilateral Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: SST Report No. 20 From the Submacular Surgery Trials Research Group. Arch Ophthalmol 125: 1323-1330 [Abstract] [Full Text]  
• Bashshur, Z. F., Schakal, A., Hamam, R. N., El Haibi, C. P., Jaafar, R. F., Noureddin, B. N. (2007). Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration. Arch Ophthalmol 125: 1357-1361 [Abstract] [Full Text]  
• Bopp, S. (2007). Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?. Br J Ophthalmol 91: 1259-1260 [Full Text]  
• Lux, A., Llacer, H., Heussen, F. M A, Joussen, A. M (2007). Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 91: 1318-1322 [Abstract] [Full Text]  
• Mori, F., Eguchi, S. (2007). Polypoidal choroidal vasculopathy. Br J Ophthalmol 91: 1104-1105 [Full Text]  
• Raftery, J., Clegg, A., Jones, J., Tan, S. C., Lotery, A. (2007). Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 91: 1244-1246 [Abstract] [Full Text]  
• Takeda, A L, Colquitt, J, Clegg, A J, Jones, J (2007). Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 91: 1177-1182 [Abstract] [Full Text]  
• Mohamed, Q., Gillies, M. C., Wong, T. Y. (2007). Management of Diabetic Retinopathy: A Systematic Review. JAMA 298: 902-916 [Abstract] [Full Text]  
• (2007). A view on new drugs for macular degeneration. DTB 45: 49-52 [Full Text]  
• Scott, I. U., Flynn, H. W. Jr (2007). The Role of Topical Antibiotic Prophylaxis for Intravitreal Injections. Arch Ophthalmol 125: 974-976 [Full Text]  
• Nakazawa, T., Takeda, M., Lewis, G. P., Cho, K.-S., Jiao, J., Wilhelmsson, U., Fisher, S. K., Pekny, M., Chen, D. F., Miller, J. W. (2007). Attenuated Glial Reactions and Photoreceptor Degeneration after Retinal Detachment in Mice Deficient in Glial Fibrillary Acidic Protein and Vimentin. IOVS 48: 2760-2768 [Abstract] [Full Text]  
• Fine, H. F (2007). Photodynamic therapy in the anti-VEGF era. Br J Ophthalmol 91: 707-708 [Full Text]  
• Peters, S., Julien, S., Heiduschka, P., Grisanti, S., Ziemssen, F., Adler, M., Schraermeyer, U., Bartz-Schmidt, K.-U., the Tuebingen Bevacizumab Study Group, (2007). Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 91: 827-831 [Abstract] [Full Text]  
• Potter, M. J, Szabo, S. M (2007). Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration. Br J Ophthalmol 91: 753-756 [Abstract] [Full Text]  
• Epstein, P. (2007). Trials That Matter: Two Faces of Progress in the Treatment of Age-Related Macular Degeneration. ANN INTERN MED 146: 532-534 [Full Text]  
• Jampol, L. M. (2007). Bevacizumab vs Ranibizumab Treatment for Age-Related Macular Degeneration: A Head-to-Head Comparison Is Needed. Arch Ophthalmol 125: 557-558 [Full Text]  
• Liew, G., Mitchell, P., Gillies, M. C., Wong, T. Y., Rosenfeld, P. J., Brown, D. M., Schneider, S., the MARINA and ANCHOR Study Groups, (2007). Ranibizumab for Neovascular Age-Related Macular Degeneration. NEJM 356: 747-750 [Full Text]  
• Chakravarthy, U., Lim, J. I (2007). New treatments for neovascular acute macular degeneration. BMJ 334: 269-270 [Full Text]  
• Arroyo, J. G (2007). Towards a rational approach to combination therapy for neovascular age-related macular degeneration. Br J Ophthalmol 91: 130-131 [Full Text]  
• Imrie, F. R., Bailey, C. (2007). New treatments for age-related macular degeneration. Age Ageing 36: 8-10 [Full Text]  
• Bhisitkul, R B (2006). Vascular endothelial growth factor biology: clinical implications for ocular treatments.. Br J Ophthalmol 90: 1542-1547 [Abstract] [Full Text]  
• Heier, J. S., Boyer, D. S., Ciulla, T. A., Ferrone, P. J., Jumper, J. M., Gentile, R. C., Kotlovker, D., Chung, C. Y., Kim, R. Y., for the FOCUS Study Group, (2006). Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: Year 1 Results of the FOCUS Study.. Arch Ophthalmol 124: 1532-1542 [Abstract] [Full Text]  
• Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., Kim, R. Y., the MARINA Study Group, (2006). Ranibizumab for Neovascular Age-Related Macular Degeneration. NEJM 355: 1419-1431 [Abstract] [Full Text]  
• Stone, E. M. (2006). A Very Effective Treatment for Neovascular Macular Degeneration. NEJM 355: 1493-1495 [Full Text]  
• (2006). New Treatment for Age-Related Macular Degeneration. JWatch General 2006: 1-1 [Full Text]